Suppr超能文献

甲状腺癌患者术后及放射性碘治疗前血清甲状腺球蛋白的预测作用

Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma.

作者信息

Signore Alberto, Lauri Chiara, Di Paolo Arianna, Stati Valeria, Santolamazza Giuliano, Capriotti Gabriela, Prosperi Daniela, Tofani Anna, Valabrega Stefano, Campagna Giuseppe

机构信息

Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, 00185 Rome, Italy.

Medical Oncology 2, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

出版信息

Cancers (Basel). 2023 May 30;15(11):2976. doi: 10.3390/cancers15112976.

Abstract

INTRODUCTION

Thyroidectomy followed by radioactive iodine therapy (RAI) is the treatment of choice for differentiated thyroid carcinoma (DTC). Serum thyroglobulin (Tg) measurement has proved to be useful for predicting persistent and/or recurrent disease during follow-up of DTC patients. In our study, we evaluated the risk of disease recurrence in patients with papillary thyroid carcinoma (PTC), who were treated with thyroidectomy and RAI, by measuring serum Tg at different time-points: at least 40 days after surgery, in euthyroidism with TSH < 1.5 and usually 30 days before RAI (Tg), on the day of RAI (Tg), and seven days after RAI (Tg).

METHODS

One hundred and twenty-nine patients with PTC were enrolled in this retrospective study. All patients were treated with I for thyroid remnant ablation. Disease relapse (nodal disease or distant disease) during at least 36 months follow-up was evaluated by serum measurements of Tg, TSH, AbTg at different time points and by imaging techniques (neck ultrasonography, I-whole body scan (WBS) after Thyrogen stimulation). Typically, patients were assessed at 3, 6, 12, 18, 24, and 36 months after RAI. We classified patients in five groups: (i) those who developed nodal disease (ND), (ii) those who developed distant disease (DD), (iii) those with biochemical indeterminate response and minimal residual thyroid tissue (R), (iv) those with no evidence of structural or biochemical disease + intermediate ATA risk (NED-I), and (v) those with no evidence of structural or biochemical disease + low ATA risk (NED-L). ROC curves for Tg were generated to find potential discriminating cutoffs of Tg values in all patients' groups.

RESULTS

A total of 15 out of 129 patients (11.63%) developed nodal disease and 5 (3.88%) distant metastases, during the follow-up. We found that Tg (with suppressed TSH) has the same sensitivity and specificity than Tg (with stimulated TSH), and it is slightly better than Tg, which can be influenced by the size of the residual thyroid tissue.

CONCLUSION

Serum Tg value, measured in euthyroidism 30 days before RAI, is a reliable prognostic factor to predict future nodal or distant disease, thus allowing to plan the most appropriate therapy and follow-up.

摘要

引言

甲状腺切除术后行放射性碘治疗(RAI)是分化型甲状腺癌(DTC)的首选治疗方法。血清甲状腺球蛋白(Tg)测定已被证明有助于预测DTC患者随访期间的持续性和/或复发性疾病。在我们的研究中,我们通过在不同时间点测量血清Tg来评估接受甲状腺切除术和RAI治疗的甲状腺乳头状癌(PTC)患者的疾病复发风险:术后至少40天,处于甲状腺功能正常且促甲状腺激素(TSH)<1.5时,通常在RAI前30天(Tg)、RAI当天(Tg)以及RAI后7天(Tg)。

方法

129例PTC患者纳入本回顾性研究。所有患者均接受碘-131治疗以消融残留甲状腺组织。通过在不同时间点测量血清Tg、TSH、抗甲状腺球蛋白抗体(AbTg)以及采用影像学技术(颈部超声检查、促甲状腺素刺激后的碘-131全身扫描(WBS))评估至少36个月随访期间的疾病复发情况(淋巴结疾病或远处疾病)。通常,在RAI后3、6、12、18、24和36个月对患者进行评估。我们将患者分为五组:(i)发生淋巴结疾病(ND)的患者;(ii)发生远处疾病(DD)的患者;(iii)生化反应不确定且残留甲状腺组织最少(R)的患者;(iv)无结构或生化疾病证据+中危美国甲状腺协会(ATA)风险(NED-I)的患者;(v)无结构或生化疾病证据+低危ATA风险(NED-L)的患者。生成Tg的ROC曲线以找出所有患者组中Tg值的潜在鉴别临界值。

结果

在随访期间,129例患者中有15例(11.63%)发生淋巴结疾病,5例(3.88%)发生远处转移。我们发现,(促甲状腺激素受抑制时的)Tg与(促甲状腺激素受刺激时的)Tg具有相同的敏感性和特异性,并且略优于可能受残留甲状腺组织大小影响的Tg。

结论

在RAI前30天甲状腺功能正常时测量的血清Tg值是预测未来淋巴结或远处疾病的可靠预后因素,从而有助于规划最合适的治疗和随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9efb/10251887/eaad68be9397/cancers-15-02976-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验